Hyun Bae
Fortuna: 15 256 $ al 31/07/2026
Fortuna: 15 256 $ al 31/07/2026
Dr. Hyun W.
Bae, MD, is an Independent Director at Kairos Pharma Ltd. and a Professor-Orthopaedic Surgery at Cedars-Sinai Medical Center.
He is on the Board of Directors at Kairos Pharma Ltd. Dr. Bae was previously employed as a Chief Medical Officer & Director by Prosidyan, Inc. He received his undergraduate degree from The Trustees of Columbia University in The City of New York and a doctorate degree from Yale University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
KAIROS PHARMA, LTD. 0,23 % | 31/03/2026 | 49.855 ( 0,23 % ) | 15 256 $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| KAIS PHARPAR | Director/Miembro de la Junta | 09/09/2020 |
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center Hospital/Nursing ManagementHealth Services Operates as a hospital | Corporate Officer/Principal | - |
| Empresas | Cargo | Fin |
|---|---|---|
Prosidyan, Inc.
Prosidyan, Inc. Industrial SpecialtiesProcess Industries Develops fiber-based bioactive glass products | Director Técnico/Científico/I+D | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
The Trustees of Columbia University in The City of New York
The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center Hospital/Nursing ManagementHealth Services Operates as a hospital | Health Services |
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prosidyan, Inc.
Prosidyan, Inc. Industrial SpecialtiesProcess Industries Develops fiber-based bioactive glass products | Process Industries |
Kairos Pharma Ltd.
Kairos Pharma Ltd. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.